<DOC>
	<DOC>NCT01211795</DOC>
	<brief_summary>Intra-Oral Topical Ketoprofen gel, applied to a branch of the trigeminal nerve, has been shown to prevent migraines when used once daily for 3 months in open label studies. This is a randomized, double-blind, placebo controlled phase III prevention trial to determine safety and efficacy.</brief_summary>
	<brief_title>Topical Intra-Oral Ketoprofen for Migraine Prevention</brief_title>
	<detailed_description>This is a 4 month trial. During the first month, a prospective headache diary is maintained. Migraine frequency, severity (1-10), duration, and all headache medications are recorded. Patients are then randomized to receive active gel or placebo gel in double blind fashion. Gel is applied to the posterior maxilla once daily for 3 months. A daily headache diary, as outlined above, is maintained throughout the trial. Patients may continue to take other migraine medications, as needed. No other new migraine therapies may be started during the trial.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ketoprofen</mesh_term>
	<criteria>IHS Migraine with or without aura 18 y.o. or older at least 4 migraines per month pregnancy other headache conditions chronic daily headache allergy or sensitivity to NSAIDs other severe illnesses</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Prevention</keyword>
	<keyword>Treatment</keyword>
	<keyword>Ketoprofen</keyword>
	<keyword>Trigeminal nerve</keyword>
</DOC>